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Targeted therapiesOncogenic mutations disrupt the regulatory circuits that govern cell function, enabling tumor cells
to undergo de-regulated mitogenesis, to resist to pro-apoptotic insults, and to invade through tissue
boundaries. Cancer cell biology has played a crucial role in elucidating the signaling mechanisms by
which oncogenic mutations sustain these malignant behaviors and thereby in identifying rational
targets for cancer drugs. The efﬁcacy of such targeted therapies illustrate the power of a reductionist
approach to the study of cancer.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction mechanisms by which oncogenic mutations endow tumor cellsOncogenic mutations disrupt the signaling systems that govern
cell fate, endowing tumor cells with several attributes that sustain
their malignant behavior. About a decade ago, it has been argued
that six enabling traits (‘‘hallmarks’’) underlie the development
of a malignant tumor: self-sufﬁciency in growth signals, insensitiv-
ity to anti-growth signals, limitless replicative potential, evasion of
apoptosis, sustained angiogenesis, and tissue invasion [1]. Since
then, it has become clear that metabolic ﬁtness and genomic insta-
bility also contribute to tumor malignancy, suggesting the exis-
tence of two additional traits [2,3]. Furthermore, a large body of
evidence has established that tumor cells must evade immune rec-
ognition [4] and recruit both angiogenic and non-angiogenic nor-
mal cells, such as macrophages, activated ﬁbroblasts, and
inﬂammatory cells, and mould a permissive microenvironment –
the tumor microenvironment – in order to progress to full malig-
nancy [5] (Fig. 1).
Modern cell biologists do not view cell biology as an approach
or group of approaches, but rather as a discipline that integrates
multiple approaches to study cell function. From this expanded
vantage point, it is possible to appreciate the contribution of cell
biology to our current understanding of tumorigenesis and, vice-
versa, the contribution of studies on cancer to our current under-
standing of normal cell function. In this Review, I will focus on
how cell biological investigations have shed light into thewith three cardinal aberrations: de-regulated mitogenesis, resis-
tance to apoptotic insults and other forms of cell attrition, and abil-
ity to invade through tissue boundaries. My choice is informed by
three considerations: (1) These three major aberrations encapsu-
late all previously described tumor cell-intrinsic hallmarks and
are the deﬁning features of malignantly transformed cells (‘‘driver
functions’’). In contrast, genomic instability and recruitment of a
tumor microenvironment foster tumor progression by enabling
and sustaining one or more of the tumor cell-intrinsic hallmarks
(‘‘Fostering functions’’) (Fig. 1); (2) Studies on cell signaling have
revealed the mechanisms by which oncogenic mutations induce
and maintain these cardinal aberrations; and (3) Blockage of onco-
genic signaling results in tumor regression in mouse models and,
increasingly so, in the clinic, validating the usefulness of a mecha-
nistic approach to the cell biology of cancer.
Loss-of-function mutation and epigenetic silencing of tumor
suppressor genes are prevalent driver alterations in cancer. My in-
tent is to provide an overview of the signaling networks in which
the proteins they encode operate and thereby introduce the
individual Reviews that comprise this special issue of FEBS Letters.
2. Cancer as a disorder of cell signaling
During development and tissue repair, individual cells or popu-
lation of cells undergo expansion in response to contextual cues
that regulate their ability to enter into and progress through the
cell cycle, to migrate, and to survive within provisional microenvi-
ronments [6]. Cell biological studies have revealed that these
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Fig. 1. Hallmarks and oncogenic functions. Deregulated signaling endows tumor
cells with several attributes (hallmarks or traits), which in turn sustain oncogenic
functions. Increased cell proliferation, decreased cell attrition, and invasion are
necessary for oncogenesis and are thus categorized as driver functions; genetic
instability and a permissive tumor microenvironment are provisionally classiﬁed as
fostering functions.
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ate – often in a tissue and cell-type speciﬁc manner – to govern the
cell cycle, anti-apoptotic, and pro-migratory machineries [7,8]. In
parallel, studies on retroviral oncogenes, on transforming genes
isolated by transfection of cancer genomes into normal cells, and
on genes identiﬁed as mutated in human cancer have indicated
that most oncogenic mutations can be mapped onto nine distinct
signaling systems [9]. Prevalent oncogenic mutations disrupt the
normal operation of these pathways leading to deregulated mito-
genesis, resistance to pro-apoptotic insults, and a gain in motility
[1]. Although biochemical and genetic analyses have played anindispensable role in elucidating the molecular underpinnings,
and thereby shaping our understandings, of the signaling systems
altered in cancer, additional approaches, such as advanced imaging
and computational modeling, have helped to place the linear
pathways deﬁned by biochemistry and genetics within spatially
organized signaling networks regulated by cross-talk and positive
and negative feedback loops [10,11]. Such an integrated approach
to cell biology has been instrumental to the development of our
current model of cancer development and to the design of thera-
pies interfering with the operation of cancer-causing genes.3. Powering the engine
3.1. Receptor tyrosine kinases
The ability of normal cells to survive and proliferate depends on
engagement of growth factor receptors endowed with tyrosine
kinase activity (receptor tyrosine kinases; RTKs) [12]. The bio-
chemical reactions that underlie RTK signaling have been eluci-
dated and placed in the context of core pathways through a
combination of genetics and biochemistry. Ligand binding and
the ensuing oligomerization of RTKs leads to phosphorylation of
tyrosine residues within the receptor tails or on surrogate proteins
(such as IRS, Gab, and FRS) creating docking sites for signaling
adaptors containing phosphotyrosine-binding domains [8]
(Fig. 2a). Shc and Grb2 are two of such adaptors and play an
essential role in recruiting the guanine-nucleotide exchange factor
SOS and thereby activating Ras. This process is facilitated by inac-
tivation of the GTPase-activating proteins p120 and neuroﬁbromin,
which is encoded by the NF1 gene. GTP-bound Ras engages multi-
ple target-effectors [13,14] (Fig. 2b). Whereas Raf commands
activation of the MEK–ERK cascade, PI(3)K, which is initially
recruited to the plasma membrane by tyrosine-phosphorylated
receptors or surrogate adaptors, enables conversion of PIP2 to
PIP3 on the inner leaﬂet of the membrane. PIP3 in turn attracts
Akt, which upon activation by PDK phosphorylates and inactivates
multiple effectors, including TSC2, GSK3-b, the CDK inhibitors p21
and p27, BAD, and FOXO transcription factors [15,16] (Fig. 3). Akt
signaling is opposed by PTEN, which dephosphorylates PIP3,
dampening recruitment to the membrane and thereby activation
of Akt [17]. Through these and additional mechanisms, receptor
tyrosine kinases promote cell survival, progression through the
G1 phase of the cell division cycle, and cell migration (Figs. 2b
and 3).
Oncogenic mutations causing deregulated activation of receptor
tyrosine kinases or their downstream signaling components are
prevalent in human cancer. HER2 is ampliﬁed in approximately
30% of breast cancers and HER1, encoding the EGFR, in a slightly
larger fraction of glioblastomas. Furthermore, activating mutations
in HER1 have been identiﬁed in the 10% or so of non-small cell lung
cancer (NSCLC)patients that responds to EGFRkinase inhibitors, and
similar and therefore potentially activating intragenic mutations in
HER2 have been found in about 4% of NSCLC patients [12,18]. Acti-
vating mutations of KIT and PDGFRA are commonly found in gastro-
intestinal sarcomas [19]. In addition, PDGF and its receptor are
overproduced in a subset of glioblastomas, although the underlying
mechanisms are unclear [12]. KRAS and BRAF mutations occur fre-
quently in multiple tumor types and are prevalent in melanoma,
pancreatic adenocarcinoma, colorectal carcinoma, and lung adeno-
carcinoma [20,21]. Activatingmutations in PIK3CA, encoding a cata-
lytic subunit of PI(3)K, occur frequently in breast, ovarian, and
colorectal cancer, and loss of heterozygosity of PTEN is one of the
most common genetic alterations observed inmultiple tumor types
[15,17]. More recently, activatingmutations in the JAK2 kinase have
been found in myeloproliferative neoplasms, KIT mutations have
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Fig. 2. Receptor tyrosine kinase signaling. (a) The membrane-proximal events and major effector pathways activated by RTKs are depicted. Ras and AKT activate multiple
targets. Signaling strength and duration are controlled by negative as well as positive feed-back loops. (b) Major signaling pathways activated by Ras proteins and multiple
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metrial carcinoma [18]. Moreover, DDR2, encoding a collagen-bind-
ing RTK, has been found mutationally activated in a small fraction
(4%) of squamous carcinoma of the lung [22]. These ﬁndings con-
ﬁrm the view that deregulatedmitogenic signaling is a major driver
of cancer development.
3.2. Cell adhesion receptors
Normal cells respond to mitogens only if they not restrained by
the inhibitory action of cadherin-mediated contact inhibition and
are attached to a supportive matrix via integrins. In contrast, neo-
plastic cells are largely insensitive to these control mechanisms
[23,24]. Cell biological studies have shed light on the major mecha-
nisms by which integrins and cadherins function as key, antithetic
regulators of mitogenic signaling in normal cells. Whereas most
integrins activate Focal Adhesion Kinase and thereby Src familykinases, certain integrins also combinewith RTKs and promote their
activation. Through these and additional mechanisms, integrins
buttress mitogenic signaling via Ras and PI(3)K and regulate Rho
familyGTPases during cell adhesion andmigration [25,26]. In agree-
ment with the hypothesis that deregulated integrin signaling con-
tributes to tumorigenesis. PTK2, encoding FAK, is ampliﬁed in a
subset of breast tumors [27], Src family kinases are often overacti-
vated in colorectal cancer [28], andDLC1, encoding aRho-GAP, is fre-
quently deleted in hepatocellular carcinoma [29].
Although the membrane-proximal signals generated by cadherin
engagement remain poorly deﬁned, recent studies have revealed that
cadherin engagement inhibits proliferation by promoting accumula-
tionof thede-phoshorylated, growth inhibitory formof the tumor sup-
pressor Merlin in the nucleus [30] as well as phosphorylation and
nuclear extrusion of the transcriptional co-activator and oncoprotein
YAP [31]. Studies inDrosophila have suggested the existenceof a linear
growth inhibitor pathway involving the Hippo kinase, the adaptor
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co-activator Yorkie (the ﬂy ortholog of YAP) [32,33]. Although genetic
analysis in the same organism suggests thatMerlin combineswith Ex-
panded at the cell cortex to activate theHippo pathway [34], studies in
mammalian cells, which lack a clear ortholog of Expanded, indicate
thatMerlinmediates contact inhibition and suppresses tumorigenesis
through inhibition of the recently identiﬁed CRL4DCAF1 E3 ligase in the
nucleus [30]. Since CRL4DCAF1 induces a tumor suppressive gene
expression program that includes the repression of a large fraction of
YAP target genes [30], it seems likely thatMerlin regulates YAP aswell
as other target genes through CRL4DCAF1. Additional events that may
contribute to contact inhibition are a consequence of the assembly of
cell junctions, which immobilize b-catenin, prohibiting its participa-
tion in Wnt signaling [35], and attenuate the activation of receptor
tyrosine kinases [36].
Increasing evidence indicates that loss of contact inhibition con-
tributes to the invasive growthof neoplastic cells.CDH1, encoding E-
cadherin, is frequently inactivated in diffuse gastric and lobular
breast cancers [37], NF2, which encodes for Merlin, is inactivated
in the cancer predisposition syndrome Type II Neuroﬁbromatosis
and in about half of malignantmesotheliomas [36], and LATS2 is de-
leted in someof the remainingmalignantmesotheliomas [38]. Final-
ly, YAP is ampliﬁed in hepatocellular carcinomas [39].
4. Fueling growth
4.1. The TOR pathway
Among downstream target-effectors of Akt, mTORC1 has
emerged as a key mediator of RTK signaling as well as a majorsensor of metabolic ﬁtness [40,41]. Following growth factor stimu-
lation, Akt phosphorylates the TSC2 subunit of the Tuberosclerosis
complex, thus inhibiting the GAP activity of this complex toward
Rheb. GTP-loaded Rheb governs the activation of mTORC1, which
in turn phosphorylates 4E-BP1 and S6K. Through these two targets,
mTORC1 promotes translation of mRNAs encoding proteins that
regulate cell growth (i.e. increase in cell mass), cell survival, and
cell cycle progression [42]. In addition, mTORC1 suppresses
autophagy (see below) and indirectly activates transcription fac-
tors, such as SREBP, PPARc and PCG1a, which promote lipid bio-
synthesis and mitochondrial function [40,41] (Fig. 3).
Various mechanisms prevent RTK-mediated activation of
mTORC1 if the extracellular or intracellular conditions are not
favorable to cell growth and cell division. Low levels of nutrients
induce a drop in the intracellular concentration of amino acids,
which is sensed by the RAG proteins, which in turn inactivate
mTORC1. In addition, decreased glycolysis and the attendant slow
down of the mitochondrial respiratory chain lead to a steep decline
in the level of ATP, causing activation of AMPK, which phosphory-
lates and thereby inactivates mTORC1. Finally, whereas DNA dam-
age-induced activation of p53 inhibits mTORC1 through activation
of AMPK, hypoxia exerts this effect through the HIF1 target gene
REDD1 [40,41] (Fig. 3). Elucidation of these signaling connections
has ﬁrmly placed mTORC1 at the center of a signaling network that
governs cell survival, cell growth, and mitogenesis in response to
growth factor stimulation.
Signaling studies have also revealed that a second TOR kinase,
mTORC2, also activated by RTKs, performs a distinct function
[40,41]. In addition to regulating the cytoskeleton through Rho
proteins, mTORC2 phosphorylates Akt at Ser 473, priming it for
Glutamine
Glutaminolysis
Myc
Pyruvate
Dehydrogenase
PDK
Myc
HIF
Oct1
Acetyl-CoA
Pyruvate
PEP
Glyceraldehyde
-3-P
FBP
ATP
Fructose-6-P
Glucose-6-P
Glucose
Lactate
MCT
PKM2RTK
Glucose
Transporter
(Glut 4)
Phospho
fructo-
kinase
Hexokinase
PI-3K
AKT NADPH
Redox
Control
Pentose
Phosphate
Pathway
Glycolysis
TIGAR
p53
HIF
Amino acid
Synthesis
Nucleotide
Synthesis
Myc Ribosome
biogenesis
and 
translation
isocitrate
NADPHIDH1/2
aKG
Lipid
synthesis
Acetye
CoA
mutant
IDH 1/2
2-HG
ATP citrate
lyase
p53
Sco2
oxidative
phosphorylation
Glutamine
Transporter
TCA
Acetyl-CoA Citrate
Fig. 4. Metabolic reprogramming in cancer. The major mechanisms by which oncogenic alterations alter ﬂux through multiple metabolic pathways are illustrated. Proto-
oncogenic proteins are in red and tumor suppressor proteins in yellow.
2562 F.G. Giancotti / FEBS Letters 588 (2014) 2558–2570further phosphorylation by the PIP3-regulated kinase PDK1 (Fig. 3).
The realization that inhibition of mTORC1 by rapamycin or
rapalogs attenuates the negative feedback loop mediated by S6K,
allowing activation of mTORC2 and thereby Akt and other SGK
kinases has provided the impetus for the development of dual
TOR–PI(3)K inhibitors, which are showing promise in early clinical
trials in gliomas, breast cancers carrying PIK3CA mutations, and
T-cell leukemias [41]. These inhibitors should also prevent release
of a recently identiﬁed additional negative feedback loop involving
mTORC1-mediated phosphorylation and stabilization of Grb10,
which opposes activations of RTKs [43,44] (Fig. 3, inset).
4.2. Metabolic reprogramming
Although it has been known for long that cancer cells utilize
predominantly anaerobic glycolysis [45], recent studies have
revealed that oncogenic mutations lead to a substantial
reprogramming of metabolism that diverts energy from aerobic
glycolysis to the synthesis of aminoacids, lipids, and nucleotides
required to fuel growth [2,46] (Fig. 4). As mentioned above, RTK
signaling through Akt activates mTORC1, which exerts an over-
arching effect on metabolism by stimulating protein and lipid
biosynthesis. In order to implement these changes, Akt promotes
the utilization of glucose by increasing translocation of membrane
transporters, such as Glut4, to the plasma membrane, and by phos-
phorylating and activating key glycolytic enzymes, such as hexoki-
nase and phosphofructokinase [2]. Deregulated Myc promotes
alternative splicing of pyruvate kinase, leading to prevalentexpression of the less efﬁcient M2 isoform (PKM2), which is further
debilitated by binding to phosphotyrosine containing proteins. The
net result is increased production of lactate at the expense of mito-
chondrial utilization of pyruvate as well as induction of the hypox-
ia-inducible transcription factor HIF1. In addition, Myc increases
the expression of genes that promote mitochondrial utilization of
glutamine and it collaborates with HIF1 to increase expression of
glucose transporters and glycolytic enzymes. On its own, HIF1 in-
duces inactivation of the pyruvate dehydrogenase complex, reduc-
ing the ﬂow of pyruvate into the tricarboxylic acid (TCA) cycle [47].
Finally, loss of p53 reduces the expression of TIGAR, which de-
creases glycolysis, SCO2, which is required for the assembly of
cytochrome c oxidase complex and therefore electron transport
in mitochondria, and PTEN, which opposes activation of Akt. One
of the key results of this metabolic reprogramming is increased
production of NAPDH and thereby of both TRX and GSH, which
buffer the reactive oxygen species (ROS) produced by oncogenic
mitogenic signaling [2,46] (Fig. 4).
While the metabolic rewiring observed in cancer is mostly
adaptive, recent studies suggest that mutations in metabolic en-
zymes can be oncogenic. A large fraction of acute myeloid leuke-
mias, gliomas, and glioblastomas harbor heterozygous mutations
in one of the two genes encoding isocytrate dehydrogenase (IDH1
and IDH2), which converts isocitrate to alpha-ketoglutarate
[48–50]. Interestingly, these mutations cause a gain-of-function
phenotype: the neomorphic enzymes can covert the a-ketoglutar-
ate produced by the wild-type allele to 2-hydroxyglutarate [51,52].
Studies of the hematopoietic system suggest that the ensuing
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of TET2, which induces global DNA hypermethylation and pro-
vokes neoplastic transformation of stem cells [53–55].
4.3. Autophagy
Studies in yeast and mammalian cells have uncovered the core
molecular machinery that controls macro-autophagy (here re-
ferred to as autophagy), the major catabolic process that governs
the degradation of long-lived proteins and organelles, providing
an essential housekeeping function [56,57]. Hormonal and meta-
bolic deprivation signals, which are sensed through inactivation
of the mTORC1 pathway, lead to activation of a Ser/Thr kinase com-
plex comprised of mATG13, ULK1/2, and the scaffold protein
FIP200. Subsequently, a lipid kinase complex comprising the class
III PI-3K mVps34, Beclin 1 (Atg6), UVRAG, and other components
mediate nucleation of a ﬂat vescicle, the phagophore. Two ubiqui-
tin-like conjugation systems, LC3-II (Atg8) and Atg12 (Atg12-5-
16L), function downstream of the lipid kinase complex to promote
expansion of the phagophore, which eventually surrounds cyto-
plasm and organelles destined for disposal and encloses them in
the autophagosome. Fusion of the autophagosome with lysosomes
allows degradation of the organelles and release of amino acids
and fatty acids that can be used by the TCA cycle to generate
ATP. Whereas mTORC1 suppresses initiation of autophagy by phos-
phorylating and inactivating mATG13, additional regulatory inputs
are provided by the antiapoptotic proteins Bcl2 and Bcl-XL, which
bind to Beclin and suppress mVps34 catalytic activity. This inhibi-
tory interaction is alleviated by pro-apoptotic proteins, such as
BH3-only proteins, DAPK, and JNK, which disrupt the association
of Bcl2 and Bcl-XL with Beclin, thus promoting autophagy.
Although autophagy and apoptosis are induced by largely overlap-
ping subsets of stimuli, the existence of different thresholds for the
activation of the two processes and of reciprocal negative regula-
tion between them explains why weak stress stimuli induce
autophagy, allowing eventual recovery, but stronger stimuli induce
apoptosis. It also explains why inhibition of apoptosis leads to
autophagic death (self-cannibalism) under conditions of stress,
whereas inhibition of autophagy accelerates apoptosis under sim-
ilar conditions [56].
Since authophagy serves a metabolic protective function under
conditions of low oxygen or nutrient availability, it may sustain the
expansion of incipient tumors that have not yet recruited a neo-
vasculature. In addition, it can promote further growth of estab-
lished tumors that have expanded beyond the functional capacity
of their defective vasculature. In agreement with this hypothesis,
Ras-dependent tumorigenesis appears to depend on the ability of
autophagy to remove defective mitochondria and thereby prevent
both oxidative damage and metabolic impairment [58,59]. On the
other side, complete loss of autophagy, such as in cells and mice
lacking Beclin, favors tumor initiation, suggesting that autophagy
may suppress tumorigenesis [56]. Autophagy may prevent normal
cells from becoming cancerous because it removes defective mito-
chondria, preventing a build up of reactive oxygen species, which
can damage the DNA. In addition, autophagy disposes of centro-
somes and other components of the mitotic apparatus that have
become defective, ensuring correct completion of mitosis. There-
fore, although autophagy can sustain tumor growth under condi-
tions of metabolic stress, its complete loss may predispose
normal cells to acquire oncogenic mutations [60].
4.4. Inputs into the cell division cycle
Progression through the cell division cycle is governed by the
periodic oscillation of cyclins and thereby the activation of their
catalytic subunits, the Cdks [61,62]. A complex loop ofubiquitin-mediated degradation events coordinate completion of
mitosis with entry in S phase, enforcing a gap phase, G1, between
the two events [63]. The presence of a G1 phase enablesmultiple in-
puts to regulate cell cycle progression. Permissive signals, such as
those transmitted jointly by integrins and RTKs, elevate the levels
of Cyclin D and thereby activate CDK4/6, which phosphorylates Rb
[64]. Liberated fromthe inhibitoryactionof Rb, the E2F transcription
factors drive expression of Cyclin E and of a myriad of factors neces-
sary forDNA replication [65].WhereasRas signaling induces expres-
sion of Cyclin D through activation of Myc and Ets transcription
factors [66], Akt blocks the ability of GSK3-b to phosphorylate Cyclin
D and to mark it for ubiquitin-dependent degradation [64]. In addi-
tion to controlling Cyclin D, mitogenic signals inactivate the CDK2
inhibitor p27kip1 through multiple mechanisms, including suppres-
sion of transcription, inhibition of nuclear accumulation, and
sequestration by active Cyclin D-Cdk4/6 complexes [67,68]. Unhin-
dered by p27, Cyclin E-Cdk2 marks p27 for degradation via the
CRL1Skp2 E3 ligase, ultimately disposing of the inhibitor [69]. Anti-
mitogenic signals, such as those activated by engagement of TGF-b
receptors, restrict progression through G1 by inhibiting the expres-
sionofMycand ID transcription factors andbyelevating the levels of
the Cdk inhibitors p21Cip1/WAF1 and p15Ink4b [68].
Oncogenic mutations target several elements of this signaling
network. Cyclin D1 is overexpressed in a large fraction of breast
cancers [70]. Myc is overexpressed as a result of chromosomal
translocation in Burkitt lymphoma and as a consequence of other
mechanisms in several other cancer types [71]. RB, which was orig-
inally identiﬁed as the tumor suppressor inactivated in familial ret-
inoblastoma, is mutated in a variety of prevalent cancers [64]. The
gene encoding p15Ink4b is inactivated as a consequence of deletion
of the INK4 locus in both solid cancers and leukemias [64]. Finally,
overexpression of SKP2 leads to severely diminished levels of p27
in various carcinomas, brain tumors, and lymphomas [67].
4.5. Disabling the brakes
Increasing evidence indicates that the emergence of carcinomas
requires avoidance of the anti-mitogenic signals provided by TGF-b
(Fig. 5a). Cell biological studies have revealed that the effects of
TGF-b are cell context-dependent: whereas differentiated epithe-
lial and endothelial cells undergo growth arrest in response to
TGF-b, other cell types proliferate and then undergo differentiation
and yet others may fail to do so or even undergo apoptosis in spite
of the presence of the correct inducing factors [72]. The signaling
mechanisms that underlie these diverse responses to TGF-b have
been elucidated to considerable detail [73]. Upon engagement by
TGF-b, the type II receptors phosphorylate and activate the type I
receptors, which initiate downstream signaling by phosphorylat-
ing the Smad 2 and 3 transcription factors. These Receptor
substrate Smads (RSmads) combine with Smad4 to form RSmad-
Smad4 complexes that migrate into the nucleus. In order to bind
with high afﬁnity and speciﬁcity to the promoters of target genes,
the RSmad-Smad4 complexes must associate with cell type-spe-
ciﬁc transcriptional partners, such as forkhead, homeobox, zinc ﬁn-
ger, bLHL, and AP1 proteins. Each RSmad-Smad4-cofactor
combination targets a speciﬁc set of genes, deﬁning so-called syn-
expression groups [72,73]. The differential response of different
cell types to TGF-b appears to be in large part a consequence of
the variegated expression pattern of the Smad cofactors and their
modulation by extracellular signals.
Since TGF-b signaling induces a cytostatic program in epithelial
cells, it is not surprising that various elements of this pathway
function as tumor suppressors in human cancer [72]. Biallelic
deletions and frameshift or missense mutations that inactivate
the TGF-b type II receptor occur in a variety of carcinomas and in
virtually all colon carcinomas with microsatellite instability.
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Smad4 is mutated in about half of pancreatic adenocarcinomas
and of colorectal cancers without microsatellite instability. Finally,
ERK-mediated phosphorylation of the linker region may target
Smad proteins for ubiquitin-dependent degradation in cancers car-
rying ampliﬁed or mutationally activated RTKs, mutant RAS, or mu-
tant BRAF. While the above alterations disable all arms of the TGF-b
pathway, enabling tumor cells to evade also the pro-differentiative
and pro-apoptotic effect of TGF-b, other mutations, such as the
inactivation of INK4 or the overexpression of Cyclin D1 or Myc,
abrogate the effect of TGF-b on CDK inhibitors allowing other
TGF-b responses to proceed unhindered [72]. In fact, inactivation
of the cytostatic arm of the TGF-b signaling pathway enables tumor
cells to usurp the other arm of the pathway to foster their malig-
nancy, as exempliﬁed by the ability of TGF-b to induce an Epithe-
lial-to-Mesenchymal Transition (EMT) and promote invasion and
metastasis in tumor cells that have lost cytostatic responses (see
below).
5. Intrinsic tumor suppression
Strong oncogenic mutations, such as those activating Ras, ele-
vating Myc, or inactivating Pten, induce apoptosis or senescence
in the majority of normal cells in which they have been acutely
introduced. These ﬁndings point to the existence of a fail-safe pro-
gram designed to eliminate incipient neoplastic cells undergoing
deregulated mitogenesis [74]. In order to overcome this intrinsic
form of tumor suppression, incipient neoplastic cells need to evade
apoptosis or senescence through the acquisition of additional
oncogenic mutations, most commonly loss-of-function mutations
of the Rb or p53 tumor suppressors (Fig. 5b).
In addition to providing a formal understanding of oncogene
cooperativity and intrinsic tumor suppression, the elucidation ofthe normal function of the Rb and p53 signaling networks has shed
light into the evolutionary advantage of these molecular circuitries
and their connection to aging. Whereas, as discussed above, Rb re-
strains G1 progression in cells that are not exposed to mitogenic
signals, the p53 trascription factor can block transit through the
cell cycle in response to multiple stress signals, including genotoxic
damage, loss of proper adhesion, and hypoxia [75]. Depending on
the level and/or quality of the stress sensed by the cell, p53 can
temporarily halt the cell cycle to allow repair or induce apoptosis
and thereby eliminate irreparably damaged cells. If the insult is
not lethal, p53 activates genes that induce transient cell cycle ar-
rest, such as p21, and allows repair of the damage through addi-
tional effectors, such as TIGAR and sestrins, which reduce the
levels of intracellular reactive oxygen species, and DRAM and
AMP-K, which activate autophagy. If the damage cannot be re-
paired and is poised to create a deranged cell potentially harmful
to the organism, p53 induces apoptosis, through activation of the
proapoptotic genes Puma, Noxa, and Bax, or promotes senescence
through induction of p21.
Although the mechanisms by which p53 is able to sense the
quality and strength of the insult suffered by the cell are incom-
pletely understood, different upstream stimuli decorate p53 with
distinct post-translational modiﬁcations, resulting in the assembly
of distinctive transcriptional complexes at the promoters of target
genes [76]. For example, DNA damage is sensed by the ATM and
ATR kinases, which in turn activate CHK2 and CHK1, respectively.
Whereas CHK1 inbibits the CDC25 phosphatase, inducing
phosphorylation and inactivation of G2 CDKs, ATM and CHK2
phosphorylate p53 at Ser 15 in the N-terminal transcriptional acti-
vation domain. In response to high levels of DNA damage, signals
initiated by ATM and ATR induce phosphorylation and inactivation
of the E3 ubiquitin ligase Mdm2, which targets p53 for degrada-
tion. In addition to driving stabilization of p53, inhibition of
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protein kinase 2 (HIPK2), which phosphorylates Ser 46 in the sec-
ond transcriptional activation domain of p53.
5.1. Suppression of apoptosis
In order to emerge as neoplastic cells, cells carrying strong
oncogenic mutations must evade apoptosis induced by oncogenic
stress [74]. In addition, suppression of apoptosis enables tumor
cells to survive under a host of stressful circumstances, such as loss
of adhesion to a supportive matrix, protracted deprivation of
growth and survival factors, and hypoxia [77].
The discovery that the proto-oncogene BCL2 is brought under
control of the Ig promoter by translocation in a subset of B-cell
lymphomas and the realization that it promotes cell survival, but
not deregulated mitogenesis, set the stage for the elucidation of
the apoptotic machinery [78]. Whereas TNF receptors are the ma-
jor activators of signal-regulated apoptosis, most if not all other
death-inducing stimuli operate by activating the so-called intrinsic
pathway of apotosis. In both the extrinsic and the intrinsic path-
way, stress signals activate BH3-only proteins, such as Bim, Noxa,
Puma, and Bid, and liberate them from stoichiometric inhibition
by Bcl2-family members [79,80]. The activated BH3-only proteins
undergo a conformational transition that enable them to combine
with Bax on the surface of mitochondria and to initiate a series of
events culminating in the release of cytochrome c and Smac/Diablo
from these organelles [81]. Cytochrome c promotes assembly of
the apoptosome complex, which drives activation of caspase 9
and 3, whereas Smac/Diablo blocks the Inhibitory of Apoptosis Pro-
teins (IAPs), which inhibit caspases [82]. Apoptosis is ﬁnally exe-
cuted through regulated, systematic proteolysis of cellular
proteins and endonucleolytic degradation of DNA [83].
Neoplastic cells evade apoptosis through multiple mechanisms.
Oncogenic signals transmitted through Ras and PI-3K promote cell
survival by inactivating Bim and Bad through multiple mecha-
nisms as well as by enhancing the expression of Bcl2 family pro-
teins and IAPs. In contrast, loss of p53 protects tumor cells from
apoptosis predominantly by reducing the expression of Puma,
Noxa, and Bax [79,80] (Figs. 3 and 5b).
5.2. Evasion of senescence
Incipient tumor cells must also avert cellular senescence in or-
der to outgrow into a neoplastic lesion. While normal cells undergo
cellular senescence in response to erosion of their telomeres or to
genotoxic damage accumulated over the years, incipient tumor
cells succumb to the same fate as a consequence of oncogenic or
replicative stress [84]. Oncogenic stress induces senescence
through induction of the CDK inhibitor p16 (e.g. Ras) or activation
of p19ARF (e.g. Myc). P19ARF in turn blocks Mdm2, allowing accu-
mulation of p53 and thereby induction of the other CDK inhibitor
p21. In contrast, replicative stress activates the DNA damage re-
sponse (DDR) and thereby directly impinges on p53 and thereby
p21 (Fig. 5b). The relative ability of oncogenic and replicative stress
to induce senescence may vary between mouse and human cells
[85].
In agreement with the hypothesis that Rb and p53 are the main
mediator of intrinsic tumor suppression andmust be inactivated for
tumor development to occur, RB and TP53 are amongst the most
commonly mutated tumor suppressor genes in human cancers
[75]. Furthermore, several cancer predisposition syndromes arise
from loss-of-function mutations in genes encoding essential
components of the DNA damage response pathway, in agreement
with the idea that loss of a functional p53 response allows the accu-
mulations of mutations that contribute to tumorigenesis [86,87].6. Disrupting the internal compass
In order to colonize distant organs, carcinoma cells need to
break from adjacent cells, disrupt the underlying basement mem-
brane, and invade through multiple tissue boundaries [88,89]. Cell
and developmental studies have shed light on the mechanisms
that enable oncogenic mutations to disrupt epithelial adhesion
and polarity and to induce a gain in invasive ability.
Apicobasal polarity, the form of polarity that characterizes epi-
thelial cells, arises from the establishment of an apical surface and
a basolateral surface, physically separated by the apical junctional
complex, consisting of tight junctions and adherens junctions.
Once cells have attached to the basal lamina via integrins and
formed initial E-cadherin-dependent adhesions, three evolution-
arily conserved polarity protein complexes generate the sets of
signals that direct the establishment of apicobasal polarity [90].
The Par3/Par6/aPKC (PAR) complex localizes to the maturing api-
cal junctional complex and governs the assembly of tight junc-
tions in response to the activation of Cdc42 and Rac. A second
complex, consisting of the transmembrane protein Crumbs and
the scaffolding proteins Pals1 and PatJ (CRB complex), localizes
to the apical-lateral boundary in response to the PAR complex
and regulates the expansion of the apical surface. Finally, a third
complex, comprising Scrib, Dlg and Lgl (SCRIB complex), deﬁnes
the basolateral surface. Whereas a reciprocally reinforcing interac-
tion between the PAR and the CRB complex helps to stabilize the
PAR complex at the apicolateral boundary, a mutually antagonis-
tic interaction between the PAR and the SCRIB complex ensures
that these complexes localize underneath opposed membrane do-
mains. In addition, while Par1 (Lkb1) localizes to the basolateral
cortex and phosphorylates and inactivates Par3 that has diffused
into this domain, the PAR complex phosphorylates and inactivates
Par-1 at the apical surface. As apicobasal polarity is being estab-
lished, vectorial delivery of vescicles containing E-cadherin and
other junctional proteins enables ﬁnal maturation of adherens
and tight junctions.
Analyses of epithelial organoids grown in 3-dimensional (3D)
matrices, such as Matrigel, have revealed that the establishment
of epithelial adhesion and polarity restrains overproliferation and
prevents apoptosis [91,92]. Normal cells that have lost contact
with the basement membrane undergo apoptosis, contributing to
the cavitation of epithelial acini. In order to induce luminal ﬁlling,
oncogenic mutations need not only to induce hyperproliferation
but also to suppress apoptosis. Furthermore, to induce invasive
growth, they must disrupt epithelial adhesion and polarity [91].
Oncogenic mutations disrupt epithelial adhesion and polarity
by various mechanisms and to varying degrees. Oncogenic RTKs,
such as ErbB2 and Met, and activated Src can phosphorylate the
cytoplasmic tail of E-cadherin and b-catenin, which tags them for
ubiquitin-dependent or lysosomal-mediated degradation. ErbB2
also coopts the b4 integrin to induce a STAT3-dependent program
of gene expression as well as it binds to Par6 to inhibit the Par
complex. In addition, activation of PI-3K or inactivation of Pten
causes depletion of PIP2, which is required for Cdc42’s function up-
stream of the PAR complex at the apical surface [93]. Finally, epi-
genetic silencing leads to underexpression of several components
of the SCRIB complex in several carcinomas, and inherited muta-
tions impair the polarizing function of LKB1 (Par4) in the familial
hamartoma Peutz-Jeghers Syndrome [94,95] (Fig. 6a).
In advanced tumors, a fraction of the constituent cells undergo
an Epithelial-to-Mesenchymal Transition (EMT), seemingly high-
jacking the developmental program deployed by normal cells to
form the mesoderm, the neural crest, and heart valves during
embryogenesis [96,97]. In addition to losing their epithelial
features, including their adhesion and polarity, cancer cells
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textual signals present in the tumor microenvironment, such as
Wnt and TGF-b family ligands, and hyperactivation of the Ras-
ERK cascade constitute the predominant culprits in most cases.
These signals produce an EMT by activating a discrete subset of
‘‘EMT-inducing’’ transcription factors [98]. Amongst these, Snail,
Slug, Zeb1, and Twist1 repress the expression of E-cadherin and
other proteins involved in the establishment and maintenance of
epithelial adhesion and polarity (occludins, claudins, Crb, Dlg,
Lgl), while FOXC2 promotes mesenchymal differentiation. Negative
and positive feedback loops mediated by microRNAs contribute to
initiate and stabilize the phenotype induced by the EMT [99]
(Fig. 6b). Interestingly, similar to normal mesenchymal cells, can-
cer cells that have undergone an EMT become at least in part
insensitive to the survival threatening effects of loss of matrix
and cell-to-cell adhesion. Furthermore, they acquire stem cell
traits, such as increased self-renewal and tumor initiation capaci-
ties [100]. It is likely that multiple of the attributes conferred by
the EMT contribute to metastatic dissemination.
While loss of cadherin-mediated adhesion facilitates and often
is a prerequisite for invasion, cancer cells can also migrate while
maintaining some degree of intercellular cohesion under a form
of migration referred to as collective cell migration [101]. The elu-
cidation of the signaling mechanisms and cellular machineries that
implement normal cellular migration has been instrumental in
building models of cancer cell migration. In normal mesenchymal
cells, integrins and cytokine receptors coordinate activation of
Cdc42 and Rac at the leading edge, promoting actin polymerization
and extension of lamellipodia. After these structures have attached
ﬁrmly to the matrix, Rho activation drives acto-myosin
contractility, favoring detachment of the cell’s rear and promoting
translocation of the cell body. Leukocytes can instead undergo an
ameboid form of movement, which is dominated by Rho kinase-
mediated contraction of the cortical cytoskeleton [102,103].
Depending on intrinsing signaling and the density and rigidity of
the surrounding matrix, cancer cells can undergo mesenchymalor ameboid migration. Integrin-mediated adhesion, hyperactiva-
tion of Rac, and a rigid, dense matrix favor mesenchymal migra-
tion, while weak adhesion, hyperactivation of Rho, and a pliable,
loose matrix promote ameboid movement [104]. Whereas the for-
mer type of cancer cell migration requires localized proteolysis of
the matrix by Matrix Metalloproteases and other enzymes, cancer
cells can squeeze through intact interstitial matrices when moving
by ameboid movement.
7. Exploiting stemness
Increasing evidence indicates that the expansion of both leuke-
mias and solid tumors is driven by a limited number of dedicated
stem cells that are capable of self-renewal as well as of aberrant
differentiation [105]. Phenotypic sorting experiments on dissoci-
ated tumor cells support the model that the cancer stem cells are
the only cells that can initiate secondary tumors upon orthotopic
implantation in immunocompatible hosts, suggesting that self-re-
newal is intimately linked to tumor outgrowth. In contrast, the
remaining tumor cells, which comprise rapidly proliferating cells
as well as aberrantly differentiated cells, are devoid of signiﬁcant
tumor initiation capacity.
In order to be deﬁned as stem cells, the cancer stem cells do not
need to phenocopy all the behaviors exhibited by embryonic or
adult stem cells. In fact, the cancer stem cells differ from embry-
onic stem cells because they do not typically give rise to multiple
lineages and they are dissimilar from adult stem cells because they
divide predominantly in a symmetric fashion. Furthermore, the
cancer stem cells do not necessarily need to arise from the trans-
formation of adult stem cells. Although certain oncogenic muta-
tions or combinations of oncogenic mutations may transform
adult stem cells, others may transform transient-amplifying cells
and confer stem cell properties upon them [106,107]. Interestingly,
recent studies have indicated that neoplastic cells undergoing the
EMT program acquire stem cell traits, suggesting that tumor cells
with transient-amplifying characteristics may be induced to
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forms of plasticity are not inconsistent with the hierarchical orga-
nization implied by the cancer stem cell model [100].
Cell biology and genetics have played key roles in the identiﬁca-
tion of signaling networks that sustain the self-renewal of normal
adult stem cells and that, when deregulated, contribute to tumor-
igenesis. Three signaling pathways, Wnt, Hedgehog (Hg), and
Notch, initially deﬁned on the basis of their developmental roles
in ﬂies, have emerged as major positive regulators in many adult
stem cells [35,108–111]. In addition, the TGF-b family ligand
BMP suppresses self-renewal and promotes differentiation, at least
in some adult stem cells, suggesting that inhibition of BMP signal-
ing may contribute to tumor initiation by blocking differentiation
[112]. Finally, the gene expression program that underlies
enhanced self-renewal may be shaped also by epigenetic modiﬁca-
tions, such as those conferred by the Polycomb component Bmi1
[113].
The evolutionarily related Wnt and Hedgehog signaling path-
ways control stem cell renewal in multiple tissues and share sim-
ilar components and a common logic of signal transduction.
Lipidation and incorporation in lipoprotein particles as well as
reversible binding to cell surface proteoglycans enable both Wnt
and Hg ligands to form extracellular gradients and thereby shape
tissue morphogenesis [114]. Moreover, in both cases the receptors
recruit multicomponent complexes that retain key transcriptional
effectors in the cytoplasm and tag them for proteolysis. Finally,
both pathways are characterized by metastable ‘‘on’’ and ‘‘off’’
states.
Like many other signaling pathways, Wnt signaling exerts dis-
tinct function depending on the cell type and developmental stage
in which it is activated. Intriguingly, Wnt signals are necessary to
drive the self-renewal of adult stem cells located at the bottom
of intestinal crypts, in the bulge region of hair follicles, in the mam-
mary gland, and in the bone marrow. When deregulated in these
cells, Wnt signaling promotes tumorigenesis, linking enhanced
self-renewal to tumor initiation. Deletions and other mutations
eliminating the scaffolding function of APC underlie the formation
of pre-malignant intestinal polyps and are prevalent in colorectal
carcinomas. Point mutations that prevent b-catenin from being
phosphorylated are found in multiple tumor types, and axin muta-
tions are found in colorectal and hepatocellular carcinomas, pro-
viding additional evidence for the role of enhanced self-renewal
in tumorigenesis [35].
Although the Hg pathway is evolutionarily related to the Wnt
pathway, it is distinctively regulated by the inclusion or exclusion
of some of its components in cilia. Although many molecular de-
tails are not yet understood, it is clear that selective incorporation
of pathway components in the cilium dictates the dual response of
the mammalian Hedgehog pathway (‘‘on’’ and ‘‘off’’ state)
[108,111]. The Hh pathway has been implicated in the mainte-
nance of stem or progenitor cells in many adult tissues, including
the epithelia of many internal organs and brain [108]. Consistent
with this, Hh signaling is critical for regeneration of the pulmonary
epithelium, prostate epithelium, and exocrine pancreas. Impor-
tantly, abnormal Hh pathway activation in some of these tissues
is also associated with tumorigenesis. Mutations in Hh pathway
components, including Ptc1 and Smo, leading to pathway activa-
tion, have been linked to basal cell carcinoma and medulloblas-
toma [115]. One hallmark of these tumors is constitutive
pathway activation in the absence of Hh ligand. In contrast, li-
gand-dependent pathway activation is important for growth, sur-
vival, or both of a wide variety of cancers, including
gastrointestinal tumors, prostate cancer, hematological malignan-
cies, and gliomas [108].
Notch signaling is initiated by the binding of Notch receptor to
Delta or another transmembrane ligand (Serrate or Lag2) on anadjacent cell. The ensuing conformational change in the extracellu-
lar domain of Notch initiates a series of proteolytic events that re-
lease the intracellular domain, allowing it to localize in the nucleus
to function as a transcription factor [109,110]. In addition to regu-
lating cell fate during development, Notch signaling is required for
the maintenance of the stem cell compartment in various normal
tissues, including the hemopoietic system [109]. Notably, more
than half of T-cell Acute Lymphoblastic Leukemias carry missense
mutations that expose the ADAM-metalloprotease cleavage site of
Notch or non-sense mutation that delete the C-terminal PEST deg-
ron of the ICN, providing strong evidence that deregulated Notch
signaling contributes to leukemogenesis. Furthermore, it has been
suggested that Notch signaling maintains the self-renewal capacity
of a stem cell-like subpopulation of tumor cells in colorectal cancer
and medulloblastoma and that it functions downstream of Wnt
signaling in breast cancer and melanoma [110].8. Hitting drivers and their underlings
Cell biological studies have played a crucial role in placing the
proteins encoded by proto-oncogenes and tumor suppressor genes
within signaling networks governing cell fate. The successive elu-
cidation of the mechanisms by which mutant versions of these
genes produce the cardinal traits of the malignant phenotype has
led to the identiﬁcation of rational targets for cancer drugs. The
extraordinary efﬁcacy of the ﬁrst of such drugs, Imatinib (Gleevec),
which blocks the kinase activity of Bcr-Abl in CML and c-Kit or
PDGFR-a in gastrointestinal stromal tumors (GIST), has provided
the ﬁrst tangible evidence of the validity of a rational approach
to cancer therapy [116]. At the same time, experiments employing
temporally regulated alleles have revealed that oncogene-deacti-
vation causes tumor regression in several mouse models of cancer,
suggesting that tumors may remain dependent on the initiating, so
called ‘‘driver’’, oncogenic lesion for their maintenance [117]. These
advances have led to the nowwidely held view that tumor cells de-
pend primarily on oncogenic signaling for their survival and
expansion, a property called oncogene dependence or addiction
[118,119]. Although the mechanisms that lead tumor cells to this
dependency are not fully understood, systems biology simulations
based on signaling data may help to decipher the rewiring of sig-
naling networks that appears to produce this effect. Needless to
say, the success of oncogene-targeted therapies is entirely predi-
cated on the existence of oncogene dependency.
The observation that EGF-R kinase inhibitors, such as Geﬁtinib
(Iressa) and Erlotinib (Tarceva), display efﬁcacy only in the subset
of patients with non-small cell lung cancer (NSCLC) carrying acti-
vating mutations in the EGF-R gene has vividly illustrated the
power but also the limits of targeted therapies: success depends
in large part on the correct identiﬁcation of the underlying ‘‘driver’’
mutation [120]. The therapeutic efﬁcacy of monoclonal antibodies
or small molecules targeting ErbB2 when used in combination with
chemotherapy for the treatment of HER2+ breast cancer and a few
other successes have provided further evidence for this model
[121]. Only recently, however, it has become evident that speciﬁc
inhibition of a mutated oncoprotein can lead to remarkable regres-
sion of an aggressive and prevalent solid tumor: the small mole-
cule PLX4032 (Vemurafenib), which targets V600E mutant B-Raf,
has been shown to induce signiﬁcant shrinkage of metastases in
about half of melanoma patients carrying such mutation [122,123].
However, although Imatinib is able to induce a complete hema-
tological response and durable remissions in the large majority of
CML patients, in fact these patients have the same life expectancy
of unaffected individuals of the same age, some patients, who have
initially responded to the drug, later develop a drug-resistant form
of the disease (therapy-induced or de novo resistance) [116,124].
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the large majority – virtually all – patients, who initially respond to
EGFR or B-Raf inhibitors, respectively, undergo relapse at a later
time [120,123]. Improved understanding of cell signaling is helping
to elucidate the mechanisms of therapy-induced resistance, so that
strategies can be designed to circumvent it. For example, most of
the relapse of CML and EGFR mutant lung cancers treated with ki-
nase inhibitors are caused by secondary mutations, which prevent
drug binding to the catalytic site without affecting kinase activity
[116,120]. Structural and functional information on tyrosine ki-
nases has been instrumental not only in identifying these mecha-
nisms of resistance but also in identifying second line inhibitors
that are able to target the kinases carrying secondary mutations
[116]. Similarly, increased understanding of cell signaling has
helped to explain the seemingly paradoxical ability of PLX4032
to activate wild type Raf signaling and to identify several potential
mechanisms of drug bypass [125]. Moreover, knowledge of the sig-
naling networks activated by tyrosine kinases is helping to design
therapies that target the pathways activated by a speciﬁc onco-
genic lesion rather than the oncoprotein itself – the only possible
approach when the driver mutation is in a tumor suppressor gene,
such as PTEN, or when pharmacological features make it difﬁcult to
target the mutated oncoprotein, as in the case of Ras [126,127]. Fi-
nally, combination therapies are being designed to prevent the
aberrant signaling that ensues upon release of the negative feed-
back loops so commonly embedded within signaling networks as
well as to ‘‘prevent’’ prevalent drug bypass mechanisms.
9. Challenges
In spite of these signiﬁcant advances and the possibility to over-
come the practical challenges outlined above, there are a number
of important theoretical issues that would need to be overcome
to extend the ‘‘Gleevec paradigm’’ to other malignancies, especially
to the most prevalent types of solid tumors.
First, in contrast to CML and certain other hematological malig-
nancies, which remain essentially monoclonal throughout their
clinical course, most solid tumors undergo clonal evolution as they
acquire additional oncogenic mutations [128]. It is likely that
malignant subclones that have acquired additional oncogenic le-
sions remain only partly dependent on the signaling pathways
activated by the initiating oncogenic mutation [116]. At present,
this model seems to provide the most plausible explanation for
the intrinsic resistance of a fraction of solid tumors to molecularly
targeted therapies. As genomic investigations of ever increasing
sophistication and power lead to the identiﬁcation of the predom-
inant oncogenic alterations present in many cancers, cell biological
and genetic studies in organotypic 3D cultures and mouse models
should help to model these tumors and characterize their proﬁles
of dependency.
Second, the cancer stem cells that are necessary for tumor
maintenance as well as the outgrowth of metastases seems to be
less sensitive to conventional as well as targeted therapy than their
immediate derivatives [129,130]. Although cancer stem cells may
be relatively drug-resistant because they cycle very slowly and ex-
press elevated levels of antiapoptotic proteins and drug efﬂux ABC
transporters, more work seems to be required to fully understand
the molecular basis of their relative resistance to targeted thera-
pies. In addition, further elucidation of the signaling networks that
sustain cancer stem cells may be needed in order to devise strate-
gies to effectively inhibit these cells.
Third, since genetic instability appears to drive the emergence
of drug-resistant clones, we need a better understanding of this
process so that we can design therapies that selectively inhibit
genetically unstable tumor cells. The efﬁcacy of PARP inhibitorsin BRCA1 and 2-mutant breast cancer illustrates the potential
power of this approach [131]. Combining drugs targeting genetic
instability with drugs targeting oncogenic signaling may be a ra-
tional approach to prevent the emergence of resistance.
Finally, most metastatic relapses from solid tumors occur years
– often several years – after initial surgery. Early dissemination of
tumor cells followed by a protracted period of dormancy at
premetastatic sites is likely to explain this prevalent clinical
behavior [132]. The genetic or epigenetic changes that allow
extravasated tumor cells to adapt and survive in a quiescent state
in the target organ remain poorly understood, and so are the mech-
anisms that enable a fraction of these cells to eventually outgrow
and give rise to macroscopic metastases [89,133]. Identiﬁcation
of the signaling networks that enable the survival of dormant tu-
mor cells and their ﬁnal outgrowth at ectopic sites may reveal
additional Achilles’s heels that could be exploited to treat meta-
static cancer.
10. Outlook
Cancer cell biology has been instrumental in elucidating the sig-
naling pathways and the molecular machineries that drive the abil-
ity of cancer cells to proliferate, to invade, and to resist attrition
(driver functions; Fig. 1) and, in so doing, in identifying rational
targets for cancer therapy. The early clinical success of several tar-
geted therapies represents, in my view, the most vivid illustration
of the power of cell biology in cancer research.
Embedded in the history of this progress is the evolution of can-
cer cell biology as a discipline. Current trends suggest that the
practitioners of this discipline will use genetic and pharmacologi-
cal methods of increasing sophistication to conduct mechanistic
investigations in an expanding range of experimental models: from
standard cell culture through 3-D organotypic cultures to animal
models. Integrated use of these approaches should provide an
increasingly detailed, 4-dimensional view of the physiology of nor-
mal and neoplastic cells in proper context.
As genomic studies on human cancer specimens and high-
throughput screens in cells and mice unveil novel and potentially
oncogenic mutations in various types of cancer [18,134,135],
mechanistic studies on the biology of cancer cells will play an
important role in assessing whether these mutations are patho-
genic and in elucidating their mechanism of action. Conversely,
studies on cell signaling will reveal novel pathways or signaling
connections implicated in the controls of the basic cellular func-
tions that sustain tumorigenesis. Whereas cancer cell biology ap-
proaches will play a key role in identifying novel potential
oncogenes and tumor suppressor genes within these pathways,
genomic studies will be required to determine if they are mutated
and at what frequency in human cancer.
Finally, a complete understanding of tumorigenesis will require
also the elucidation of the complex signaling circuits that regulate
the tumor microenvironment, thus fostering tumor progression
and metastatic dissemination [5,136]. Although the composition
and function of the tumor microenvironment may ultimately be
dictated by the spectrum of genetic and epigenetic changes ac-
quired by tumor cells as well as their histological origin, future
studies may be able to distill core pathways that play a role in mul-
tiple tumor types. The ability of HIF1 and its transcriptional target
VEGF to mediate neoangiogenesis [137], NF-jB to support tumor
inﬂammation [138], and TGF-b to mediate wound healing and
ﬁbrosis and suppress immune recognition [72] may explain their
ubiquitous roles in the tumor microenvironment. Agents that tar-
get these or other core signaling pathways that sustain the tumor
microenvironment may display efﬁcacy when used in combination
with oncogene-targeted therapies.
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the discovery of oncogenes and the initial success of targeted ther-
apies, one cannot avoid but being cautiously optimistic about the
future of cancer research [139]. Unless myopic concerns over gov-
ernment spending restrict investment in basic science in the U.S.
and Western Europe, reversing a long standing trend of global
expansion of the scientiﬁc enterprise, one can anticipate that re-
search on the biology of cancer will ultimately lead to dramatically
improved treatments for many prevalent cancers.
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